Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. by Barzaghi, Federica et al.
UCSF
UC San Francisco Previously Published Works
Title
Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An 
international multicenter retrospective study.
Permalink
https://escholarship.org/uc/item/56g0d17d
Journal
The Journal of allergy and clinical immunology, 141(3)
ISSN
0091-6749
Authors
Barzaghi, Federica
Amaya Hernandez, Laura Cristina
Neven, Benedicte
et al.
Publication Date
2018-03-01
DOI
10.1016/j.jaci.2017.10.041
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Long-term follow-up of IPEX syndrome patients after different 
therapeutic strategies: An international multicenter retrospective 
study
A full list of authors and affiliations appears at the end of the article.
Abstract
Background—Immunodysregulation polyendocrinopathy enteropathy x-linked(IPEX) 
syndromeis a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare 
disease, the natural history and response to treatments, including allogeneic hematopoietic stem 
cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined.
Objective—This analysis sought to evaluate disease onset, progression, and long-term outcome 
of the 2 main treatments in long-term IPEX survivors.
Methods—Clinical histories of 96 patients with a genetically proven IPEX syndrome were 
collected from 38 institutions worldwide and retrospectively analyzed. To investigate possible 
factors suitable to predict the outcome, an organ involvement (OI) scoring system was developed.
Results—We confirm neonatal onset with enteropathy, type 1 diabetes, and eczema. In addition, 
we found less common manifestations in delayed onset patients or during disease evolution. There 
is no correlation between the site of mutation and the disease course or outcome, and the same 
genotype can present with variable phenotypes. HSCT patients (n = 58) had a median follow-up of 
2.7 years (range, 1 week-15 years). Patients receiving chronic IS (n = 34) had a median follow-up 
of 4 years (range, 2 months-25 years). The overall survival after HSCT was 73.2% (95% CI, 
59.4-83.0) and after IS was 65.1% (95% CI, 62.8-95.8). The pretreatment OI score was the only 
significant predictor of overall survival after transplant (P = .035) but not under IS.
Conclusions—Patients receiving chronic IS were hampered by disease recurrence or 
complications, impacting long-term disease-free survival. When performed in patients with a low 
OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor 
source, or conditioning regimen.
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The immunodysregulation-polyendocrinopathy-enteropathy x-linked (IPEX) syndrome is a 
primary immunodeficiency caused by hemizygous mutations in the gene FOXP3, which 
encodes an essential transcription factor required for maintenance of immunologic tolerance 
by thymus-derived regulatory T (Treg) cells. Since its first clinical description in 19821 and 
its genetic characterization in 2001,2,3 IPEX syndrome has gathered the attention of 
scientists and physicians as the prototype of a monogenic autoimmune disease and immune 
deficiency affecting the immune regulatory compartment.4,5 Significant advances have been 
made in elucidating the complex disease pathogenesis.6–9 The typical manifestations of 
severe enteropathy, type 1 diabetes (T1D) and eczema have been extensively reported, but 
IPEX still poses a significant therapeutic challenge. Single reports of young adults affected 
by “atypical” or “late onset” IPEX forms have suggested heterogeneity in both the clinical 
presentation and their response to therapy.10–12 Immunosuppressive therapy, the first-line 
treatment for IPEX patients, has changed considerably in recent years with the introduction 
of new drugs with an immune suppressive and modulatory action. Nevertheless, the use and 
efficacy of these therapies are largely undocumented in IPEX patients. Currently, the only 
potentially curative therapy for IPEX syndrome is allogeneic hematopoietic stem cell 
transplantation (HSCT) with the longest published follow-up of 8 years.13,14 Both HLA-
identical and matched-unrelated HSCT can be successful. However, while there is a general 
understanding to treat early, a comprehensive study comparing different transplant protocols 
and long-term outcomes is not available. In addition, a significant number of patients cannot 
undergo HSCT, due to limited donor availability and high risk-benefit ratio. Finally, older 
patients with a mild disease phenotype, in whom the clinical manifestations are often not 
severe enough to justify HSCT, raise concerns regarding the appropriate treatment.15
This international multicenter retrospective analysis of IPEX patients aims to provide a 
comprehensive view of the disease, its evolution, and outcomes of different therapeutic 
strategies. We aim to unveil limitations of case reports or small case series by providing a 
more comprehensive analysis of a large patients’ cohort. Ultimately, our work aims to 
improve the diagnosis and the long-term treatment for IPEX syndrome, with the goal of 
achieving definitive cure, which could apply to other immunodeficiencies with 
autoimmunity.
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METHODS
Patients’ cohort and definitions
A retrospective multicenter study was performed in which data were collected from 38 
institutions worldwide. All patients included were diagnosed with IPEX syndrome based on 
the presence of a FOXP3 mutation (detected but not specified for 5 patients). Data were 
collected through a detailed survey. Each center notified to their institutional review board 
and, if required, obtained the approval for sharing the data included in the present study. 
Data were transferred in a completely deidentified form.
Clinical manifestations were defined as “autoimmune” based on exclusion of other causes, 
the presence of specific autoantibodies or presence of other pathological findings suggestive 
of autoimmune etiology, or ex juvantibus (positive response to immunosuppressive therapy). 
Based on the number of organs or systems impaired by the autoimmune damage or by 
secondary complications, before undergoing immunosuppression (IS) or HSCT, we 
established an organ involvement (OI) scoring system ranging between 0 and 5; 1 point was 
assigned for the presence of each of the following: intractable diarrhea, malnutrition, liver 
dysfunction, respiratory impairment, kidney dysfunction. The selection of these parameters 
was dictated by their relevance in affecting disease morbidity and survival. The presence of 
clinical manifestations was assessed by the caring physicians, according to standard of care 
definitions.
The effect of IS was considered “beneficial” when the physician observed a decrease (partial 
benefit) or complete disappearance (benefit) of signs and symptoms of the disease.
Conditioning regimens were defined as fully myeloablative (full) or as reduced intensity 
transplant (RIT). Full conditioning regimens included busulfan plus cyclophosphamide, 
busulfan of > 14 mg/kg or cumulative area under the curve of 80 to 90 mg × h/L (when 
available) plus fludarabine, or treosulfan. RIT encompassed both reduced intensity 
conditioning (eg, fludarabine plus nonmyeloablative doses of busulfan, treosulfan, or 
melphalan) and minimal intensity conditioning (eg, fludarabine plus low dose radiation or 
cyclophosphamide).16
Neutrophil engraftment was defined as the first of 3 consecutive days with neutrophils 
>1000 per mm3 unsupported; platelet engraftment was defined as the first of 3 days with 
platelets >50,000 per mm3 unsupported. A “boost” was an additional infusion of HSC 
without conditioning, while “second or third” transplants were additional infusions of HSC 
from a different donor with conditioning. T-cell reconstitution (analyzed at 3, 6, and 12 
months and at the last available follow-up) was defined as >1000 CD3+ T cells per mm3, 
>500 CD4+ T cells per mm3 and presence of proliferative response to mitogens (considered 
as positive when within the normal range of the laboratory). B-cell reconstitution was 
defined as independence from immunoglobulin replacement therapy. Full conditioning 
regimen donor chimerism was defined as >95% donor cells in peripheral blood (evaluated at 
3, 6, and 12 months and at last follow-up). Primary graft failure was defined as absence of 
donor cells in peripheral blood posttransplant. Secondary graft failure was defined as 
reduction of neutrophil counts, occurring after engraftment, and absence of donor cells 
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(below 5%), despite normal blood counts. The diagnosis and grading of acute or chronic 
graft-versus-host disease (GvHD) were based on previously published criteria and scoring 
system.17
Evaluation of quality of life was reported by the caring physicians without a standardized 
scoring system (yes/no questions).
Statistical analysis
Demographic, disease-related, or transplant-related characteristics were reported as 
frequencies for categorical variables, and median and range for quantitative variables. 
Associations between variables and disease outcome or type of treatment were compared 
with the use of the chi-square test (categorical variables) or unpaired t-test (continuous 
variables).
Probabilities of survival after treatment and disease-free survival (DFS) were computed with 
the use of the Kaplan-Meier estimator and compared with the log-rank test (Mantel-Cox). 
We then used a multivariable analysis to examine risk factors for transplantation outcomes 
and adjust for confounding factors using the Cox (proportional hazard) regression models 
with Breslow estimator; a P value of .05 or less was considered statistically significant. The 
variables considered in the Cox regression to model transplantation outcome were age at 
transplant, pre-HSCT OI score, donor type, degree of HLA-matching, intensity of 
conditioning regimen, graft source, and number of CD34 cells infused. For a small cohort of 
patients transplanted at <1 year, the variables used in the Cox regression were age at HSCT, 
score, and weight. We also examined DFS with a Cox regression model, where death is 
treated as a censoring event, using as predictor variables the score pre-HSCT, graft failure, 
and conditioning.
The patients whose mutations were known (n = 91) were grouped in 4 categories depending 
on type of mutation: missense, splice site, frameshift or in-frame deletions or insertions; and 
“others” including mutations in the untranslated region, promoter, or start codon. We 
furthermore explored each mutation effect on protein function through available algorithms 
such as PolyPhen-2 (providing predictions for amino acid substitutions) and PROVEAN 
(providing predictions for amino acid substitutions, insertions, and deletions), obtaining a 
numeric score and a qualitative prediction outcome such as “benign” or “neutral,” and 
“deleterious” or “probably damaging.” We examined associations among the predicted 
protein scores and each patient score before HSCT or IS and their survival outcome, by 
evaluating Spearman correlation coefficient and contingency tables.
RESULTS
Initial clinical manifestations, disease course, and genetics
Ninety-six patients with FOXP3 mutations were included in our study. The median age at 
disease onset was 2 months (range, birth to 11.3 years): 41% had onset within the first 
month of life, 46% between 1 month and 1 year, 10% after 1 year of age, and for 3% of 
patients, the time of onset was unavailable. The median time to diagnosis (elapsed time 
between onset of symptoms and genetic diagnosis) was 14 months (up to a maximum of 
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23.9 years) (Fig 1, A); however, the number of IPEX patients diagnosed per year shows an 
increased trend (Fig 1, B).
The most common presentation suggestive of the diagnosis of IPEX syndrome remained the 
classical triad of enteropathy, T1D, and eczema for the majority of the 39 of 96 patients who 
had neonatal onset. Gastrointestinal involvement and eczema, but not T1D, were the 
dominant features of disease presentation after 1 month of age. However, failure to thrive 
was a hallmark of the disease and it was sometimes the sole initial manifestation after 1 
month of age. After 1 year of age, the disease could also present with nephropathy or 
hepatitis, otherwise considered atypical at onset (Fig 1, C and D).
The symptoms observed over the course of the disease and their prevalence are listed (Fig 1, 
D): with the exception of diarrhea, eczema, and failure to thrive, nephropathy (autoimmune 
or secondary to malnutrition and medication) was the most common (33 of 96 patients), 
varying from lithiasis, nephrocalcinosis, or isolated proteinuria to more severe 
manifestations such as nephrotic syndrome (in some cases with a definite diagnosis of 
glomerulonephritis) or tubulopathy and interstitial nephritis. Hematological manifestations 
included autoimmune hemolytic anemia (25 of 96 patients), thrombocytopenia (13 of 96 
patients), and neutropenia (6 of 96 patients). Other conditions included autoimmune 
thyroiditis (15 of 96 patients) and hepatitis (19 of 96 patients), while food allergies (13 of 96 
patients), arthritis (8 of 96 patients), alopecia (8 of 96 patients), and lymphadenopathy (9 of 
96 patients) were occasionally reported during disease progression. Interestingly, among 
other uncommon manifestations (Fig 1, E), neurological findings, of uncertain relation with 
FOXP3 mutations, were reported in 16 of 96 patients, including peripheral neuropathy, 
myopathies/ hypotonia, hemidiaphragmatic paralysis, eosinophilic meningitis, 
neurodevelopmental delay, seizures, and benign intracranial hypertension.
The 96 patients included in the study displayed 33 published mutations4,5 and 21 novel 
mutations. The forkhead (FKH) domain emerges as a mutational hotspot of the FOXP3 gene 
(Fig 1, F), although mutations were scattered along the gene. Mutations in the N-terminal 
and FKH domains correlated with high variability of age at onset. The number of symptoms 
at onset was independent from the site of the mutations.
Laboratory findings
Table I summarizes the biological findings characterizing this IPEX patients’ cohort before 
therapy. The distribution of lymphocyte subsets before IS or in patients treated with long-
lasting IS or before HSCT was normal or seldom characterized by increased counts. The 
proportion of Treg cells, evaluated by flow cytometry, was available only in few patients and 
FOXP3 showed a wide range of expression. Gut biopsies frequently showed simultaneous 
involvement of several sites: the most common target was the small bowel, followed by large 
bowel, stomach, and esophagus. The inflammatory infiltrates were usually polymorphic with 
predominance of lymphocytes and eosinophils. Villous atrophy remained the hallmark of 
IPEX enteropathy, although other nonspecific lesions associated with inflammatory damage 
(ulcers, crypt hyperplasia, and abscesses) were present. Of note, 4 patients showed 
metaplastic lesions, either in the bowel or in the stomach, and 1 developed dysplastic lesions 
of the gastric mucosa. Antienterocyte, antiharmonin, or antivillin autoantibodies were 
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positive in 33 of 42 patients with enteropathy tested (Table I). In contrast, in 9 of 42 cases 
these autoantibodies could not be detected despite the presence of enteropathy, a finding 
possibly dependent on the choice of antibodies that were tested. Remarkably, in 1 case, 
antiharmonin autoantibody positivity prompted the diagnosis in a patient with isolated 
IPEX-related gastritis. Antineuron antibodies were detected in 1 of the patients with 
neurological involvement. Finally, 12 patients screened positive for T1D-associated 
autoantibodies (2 of them had 2 positive auto-antibodies), without having T1D (Table I). 
Thus, the histological and serological markers were indicative of the diagnosis only when 
considered together with the clinical manifestations.
Treatments
Of the 96 patients included in the study, 34 received IS and 58 underwent HSCT. Four 
patients with FOXP3 mutations improved spontaneously (1), did not require IS (2), or were 
still asymptomatic (1) and were thus excluded from this analysis. One patient had several 
manifestations of the disease (enteropathy, growth retardation, eczema, autoimmune 
cytopenia) that improved spontaneously, with supportive therapy and without any 
immunosuppressive drugs. Two other patients had persistent signs of the disease that, 
however, did not require IS (eczema and growth retardation in 1 case and T1D in the other). 
The last patient is still asymptomatic at 6 years of age, and he was diagnosed only due to 
familial history. Fig 2 provides a schematic view of the disease evolution of each patient and 
his mutation and reveals the variability of disease progression in our cohort.
Immunosuppressive therapy
The 34 patients who received IS and were not transplanted started treatment at a median age 
of 1.5 years (range, 1 month-19.6 years) with a median follow-up of 4 years (range, 1 
month-25 years). Only 3 patients had a follow-up shorter than 7 months.
Fig 3 shows the response to each drug, to drug combinations, and the final outcome after IS. 
Twenty-five patients received systemic steroids (range, 2 months-22 years; median, 2 years). 
While steroid administration benefited 56% of the treated patients, it was often administered 
concomitantly with other immunosuppressive drugs (Fig 3, B), thus direct effects cannot be 
confirmed.
Twenty patients received calcineurin inhibitors, either cyclosporine-A or tacrolimus, with 
benefit in 40% (Fig 3, A). Six of them also received concomitant steroids and 3 both steroids 
and noncalcineurin inhibitors. Among patients treated with noncalcineurin inhibitors, 15 
patients received rapamycin and 19 received other immunosuppressive agents comprising 
azathioprine, methotrexate, mycophenolate-mofetil, mesalazine, sulfasalazine, and 6-
mercaptopurine. Combination of steroids with calcineurin inhibitor, noncalcineurin 
inhibitors, or both (12 of 21 patients) infrequently (1 of 12 patients) led to remission of 
autoimmunity (Fig 3, B). Rapamycin improved autoimmune manifestations in 67% of 
patients (Fig 3, A) and in 8 of 10 patients when it was used as monotherapy, with 6 of 8 
patients achieving remission (Fig 3, B). The use of azathioprine was beneficial in 36% of 
cases (Fig 3, A). The use of mAbs, including anti-TNF-α, anti-CD20, and cytotoxic T 
lymphocyte–associated antigen 4 fusion protein (abatacept), was usually in addition to other 
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IS; therefore, their efficacy as single drugs is not fully evaluable. Although treatment with a 
mAb was beneficial in the 52% of cases (Fig 3, A), mAb-based regimens rarely resulted in 
sustained remission of autoimmunity (2 of 8 patients) (Fig 3, B).
Prior to initiation of IS, 25 of 34 patients were malnourished (74%) and 26 of 34 had 
intractable diarrhea (76%). The prevalence of these clinical manifestations significantly 
diminished following IS, since malnutrition persisted in 10 cases (29%; P < .001) while 
diarrhea persisted in 7 cases (20%; P < .001). Similarly, 3 of 5 patients with autoimmune 
hepatitis improved after IS. Nevertheless, prevalence of respiratory impairment, kidney 
dysfunction and frequency of infections increased under IS although not significantly (P = .
538, P = .511, and P = .627) (Fig 3, C).
Overall, 10 of 34 patients receiving IS completely controlled autoimmunity, while 24 
patients still had autoimmune manifestations, mainly enteropathy (11 of 24). T1D remained 
the only autoimmune manifestation in 2 patients. In 11 patients new autoimmune 
manifestations arose while receiving IS, including T1D (4), thyroiditis (3), autoimmune 
cytopenia (2), autoimmune hepatitis (2), enteropathy (1), adrenal insufficiency (1), and 
arthritis (1). Overall, the OI score before starting IS mostly corresponded to the OI score at 
disease onset and did not significantly influence the outcome. Indeed, most of the patients 
improved in the short term; whereas in the long term, the OI score could worsen due to 
disease recurrence or progression and side effects of treatment, thus impacting survival (Fig 
3, D), as discussed below.
Nutritional support (enteral, parenteral, or both) was often necessary for patients under IS 
(19 of 34), lasting for months or years. Recurrent hospitalization for disease complications 
and infections occurred a median of 4 times per year (ranging from 0 to 7 times per year). 
Thirty of 34 patients are alive at the last follow-up. Four patients died (at 5 months, and 1.5, 
7, and 22.5 years, respectively). Causes of death were acute respiratory distress syndrome 
with multiple organ failure, pneumonia, idiopathic cardiac arrest, and sepsis. The estimated 
overall survival of patients under IS was 86.8% (95% CI, 62.8-95.8) at 15 years and 65.1% 
(95% CI, 18.3-89.7) at 24 years.
Thus, the merely symptomatic approach of long-term IS can be beneficial in the short term, 
but it did not prevent disease progression and development of complications in the majority 
of the patients and it could have an impact on patients’ survival.
Hematopoietic stem cell transplantation
Fifty-eight patients underwent HSCT. Seven patients required a second transplant and 1 
patient received 3 HSCTs. In these patients, follow-up records refer to the last procedure. 
The median follow-up was 2.7 years (range, 2 weeks-15 years). The median age at onset for 
patients in this cohort was 1 month (range, birth-1 year) and transplant was performed at a 
median age of 1.4 years (range, 1 month-18.8 years), indicating that the majority of the 
transplants were performed at early age and close to disease onset (see Fig E1, A in this 
article’s Online Repository at www.jacionline.org). Despite the short time frame between 
onset and transplantation, 54 patients received IS prior to transplantation. Disease 
manifestations improved before HSCT in 27 of 54 patients, while 23 of 54 patients had 
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partial or no control of the autoimmune manifestations and 4 of 54 patients could not be 
assessed for response. Application of the OI score at the time of transplantation 
demonstrated a strong association with outcome. The estimated overall survival after HSCT 
was 73.2% at 15 years, with significant differences for patients with either low or high OI 
score, as described below.
HSCT characteristics and complications
The majority of patients (33 of 58) received RIT (Table II; see also Table E1 in this article’s 
Online Repository at www.jacionline.org for further details about conditioning). Donor type 
included matched related (31 of 58 patients), matched unrelated (21 of 58 patients), 
haploidentical (5 of 58 patients, 3 of which had α/βT-cell depletion), and other (1 
mismatched related of 58 patients). HSC sources included bone marrow (35 of 58 patients), 
peripheral blood stem cells (12 of 58 patients), and cord blood (13 of 58 patients). 
Antithymocyte globulin or alemtuzumab were frequently used (49 of 58 patients). GvHD 
prophylaxis mainly consisted of cyclosporine-A associated with mycophenolate-mofetil or 
steroids. Hematological recovery was obtained at a median of 16 days for neutrophils and 20 
days for platelets. At 1 year after HSCT, 22 of 33 patients had achieved T-cell reconstitution. 
At a median of 14.5 months, 20 of 29 patients had positive proliferative response to 
mitogens. Independence from IVIG was reached at a median of 7 months in 30 of 45 
patients. Transplant-related toxicity was observed in 11 cases (19%). Multiple infections 
were reported in 46 patients (85%).
GvHD—Nineteen of the transplanted patients (33%) experienced acute GvHD, which was 
of grade III to IV in 9 patients. Among patients surviving >100 days, 6 of 52 developed 
chronic GvHD (10% of the transplanted patients). While not statistically significant, the 
incidence of acute GvHD was higher in patients who did not receive serotherapy (5 of 9; 
55%) compared with those receiving antithymocyte globulin or alemtuzumab (16 of 47; 
34%), for 2 patients GvHD could not be ascertained. Occurrence of acute GvHD was 
comparable (P = .2362) in related (5 of 17; 29%) and unrelated (15 of 31; 48%) donor 
transplants. Overall, the incidence and severity of GvHD for IPEX syndrome were similar to 
that described for other primary immune deficiencies.18
Chimerism—Full donor peripheral blood chimerism was detected in 31 of 53 patients 
evaluated for chimerism; 17 of them were alive and in remission (or with T1D only). Among 
the patients with full donor chimerism, 3 died and 11 had autoimmune manifestations (or 
GvHD). Mixed chimerism was detected in 18 of 53 patients and associated with disease 
remission in 9 of 18 (Fig E1, B). Importantly, the Treg cells were 100% of donor origin in 3 
of 9 patients carrying mixed chimerism in remission. Moreover, 4 of 18 patients with mixed 
chimerism are alive with autoimmune manifestations (Fig E1, C) and 5 of 18 patients have 
died—all but 1 of infections, at different times post-HSCT (Fig E1, D). The occurrence of 
mixed chimerism was not related to the use of RIT and was also observed following fully 
myeloablative conditioning. Overall, the data show similar proportion of patients in 
remission among those with full (17 of 31, 54%) or mixed (9 of 18, 50%) chimerism. In 
addition, graft failure was observed in 4 of 53 patients (Fig E1, E). Two patients experienced 
secondary graft failure between 3 and 6 months posttransplantation, they are still alive but 
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with disease relapse. The other 2 patients are dead, 1 with primary graft failure and the 
second with acute graft loss 40 days after transplant.
Survival after transplant—The estimated overall survival rate for transplanted patients at 
15 years was 73.2%. The majority of deaths occurred in the first months after HSCT due to 
infections. Multivariable analysis showed that the type of conditioning, type of donor, and 
age at transplantation did not significantly influence survival (Fig 4, A-C). In fact, the pre-
HSCT OI score was the only variable significantly influencing survival after HSCT. Indeed, 
the probability of survival was significantly lower in patients with a score between 3 and 5 
as compared to patients with an initial score between 0 and 2 (P = .002) (Fig 4, D). In 
addition, the combined analysis of the score and of the conditioning regimen, showed that 
patients with scores 0 to 2 had better survival independently of the administration of full 
conditioning or RIT. Within the same analysis, patients with scores 3 to 5 who received full 
conditioning had better survival than the ones who received RIT (Fig 4, E). Similarly, the OI 
score affected the survival outcome among patients below or above 1 year of age, with 
patients <1 year and high score performing significantly worse (Fig 4, F). The majority of 
patients who were <1 year of age at the time of HSCTwere also at or below the third centile 
for weight (16 of 21 patients whose weight at transplantation was reported). Among these 
patients, we further observed that the patients who did not survive had lower weight and 
younger age, although the number of events was not sufficient to perform a multivariable 
analysis (see Fig E2, A and B in this article’s Online Repository at www.jacionline.org). 
DFS analysis showed that the probability of recurrent or new onset autoimmunity after 
transplantation was not dependent on the conditioning administered (Fig E2, C) or 
chimerism obtained after transplantation (Fig E2, D). Multivariable analysis did not identify 
a variable significantly affecting DFS after HSCT.
Comparison of outcomes between transplanted and not transplanted patients
—Survival rates at 15 years among children undergoing HSCTwere lower, although not 
significantly, as compared to those receiving chronic IS (73.2% vs 86.8%; P = .055) (Fig 5, 
A). This difference is largely due to the high mortality rate within 2.5 years following 
transplantation, with up 15% of patients dying by the first 100 days and 25% by the first 2.5 
years (Fig 5, A). Patients who survive over 2.5 years after transplant do not show additional 
mortality up to 15 years later, and their probability of survival remains constant, whereas 
that of IS patients, who have a longer follow-up, drops as the disease progresses and 
treatment complications increase with time (survival rate at 24 years is 65.1%). Indeed, the 
survival of patients receiving IS does not depend on the OI score pre-IS but, in the long-
term, a worsening of the OI score can negatively influence the survival in these patients. 
Thus, the OI score post-IS is significantly correlated with survival (P = .0444) (Fig 3, D).
The percentage of patients who completely resolved autoimmunity (or had only T1D) was 
higher in alive transplanted patients than in those receiving IS, although not significantly 
(56% vs 36%, P =.083). Similarly, the persistence or the onset of new autoimmune 
manifestations (other than GvHD in transplanted patients) was significantly lower in patients 
surviving HSCT than under IS treatment (17% vs 51%, P = .001) showing that IS does not 
prevent disease progression. This latter conclusion is also supported by the DFS curve 
Barzaghi et al. Page 9
J Allergy Clin Immunol. Author manuscript; available in PMC 2018 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
showing a progressive reduction of DFS probability during IS. On the contrary, DFS 
probability remains stable after the first 6 years posttransplant (Fig 5, B).
We did not observe any significant correlation between disease score or survival and the 
effect of the different mutations on the FOXP3 protein, as predicted by PolyPhen-2 or 
PROVEAN, for patients given either IS or HSCT (see Fig E3 in this article’s Online 
Repository at www.jacionline.org).
In the entire cohort from 28% (under IS) to 31% (after HSCT) of the patients experienced 
delayed neuromotor development or needed a support teacher, despite comparable rates of 
patients undergoing schooling/working activities adequate for age after either therapeutic 
approach. Of note, a significant percentage of children needed psychological support. 
Nutritional issues lead to a frequent and prolonged use of feeding support in both categories. 
In line with the outcome results, a significant percentage of patients surviving HSCT 
considered this therapy efficacious. In contrast, patients undergoing IS perceived an 
incomplete resolution of the disease and complained about chronic medications, side effects, 
and periodic follow-up (see Table E2 in this article’s Online Repository at 
www.jacionline.org). This confirms that patients surviving transplantation are less prone to 
disease evolution and complications over time.
DISCUSSION
The present retrospective study of IPEX patients provides an informative comparison of the 
currently available therapeutic options and their long-term outcome, together with a 
comprehensive and updated view of the disease and its initial presentation and progression. 
We demonstrate that IPEX patients have similar overall survival, regardless of whether they 
receive IS or HSCT, with a greater survival in the first years posttreatment for the non-HSCT 
group. However, the DFS of HSCT patients shows clear differences with stable resolution of 
autoimmunity as compared to the persistent disease progression in the nontransplanted IPEX 
patients. Therefore, the study highlights the therapeutic limitations of the current 
immunosuppressive regimens, although the use of rapamycin proved as the most beneficial 
IS therapy11,19,20 and appears to be superior to calcineurin inhibitors.13,21–24 Results from 
this study further indicate that a better survival outcome after HSCT is significantly affected 
by the patients’ pre-HSCT conditions, as defined by the OI score we established. IPEX 
patients with low OI score, either initially or after IS, had a survival advantage after HSCT. 
On the contrary, IPEX patients with severe organ impairment (high OI score) at HSCT had 
the lowest chance of survival even receiving a RIT, suggesting that the clinical status is more 
important than the conditioning regimens in the outcome of HSCT. Other variables (ie, type 
of donor, stem cells source, and chimerism) were not correlated with outcome, as was 
previously reported in a small cohort of patients.25 In contrast though with this other cohort,
25
 our data show that patients transplanted before 1 year of age tended to have a lower 
survival (although without statistical significance), which may reflect either a more severe 
disease status or an increased sensitivity to conditioning agents. Overall, these data point to 
the value of optimizing patient’s clinical condition prior to HSCT and considering HSCT 
before disease progression.
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The majority of the patients in our study received a RIT,25–30 conditioning that is not always 
associated with mixed chimerism, frequently observed in IPEX transplanted patients.
13,14,21,25,26,30
 Mixed rather than full donor chimerism did not affect DFS probability, as has 
been the case for other primary immunodeficiencies.31 Importantly, in a small number of 
IPEX patients14,30 with mixed chimerism who achieved remission, all Treg cells were of 
donor origin, indicating that the presence of functional Treg cells may suffice to control 
autoimmunity and supporting the importance of evaluating lineage-specific chimerism.
In addition to the analysis of outcomes, results from the present data collection strengthen 
the notion that the disease onset is usually early, with half of the patients presenting within 
the first month of life. We show that enteropathy, T1D, and eczema are the initial symptoms, 
especially in neonates, while in the later onset patients, failure to thrive becomes a 
predominant symptom at presentation. With the increasing number of IPEX patients 
diagnosed over time, a group of asymptomatic patients or patients initially presenting with 
only T1D have been identified. With disease progression, multiple other autoimmune 
symptoms arise with blood, kidney, and liver frequently targeted. Unexpectedly, 
neurological impairment, respiratory involvement, and cardiac complications have been 
often observed, though their autoimmune origin rather than toxic or infectious pathogenesis 
remains unclear and should be investigated in a prospective study. As has been previously 
suggested,9,32 it is difficult to correlate the site of mutation with disease course or outcome. 
For example, mutations in the FKH domain, required for FOXP3 nuclear localization and 
DNA binding, correlated with the earliest onset, while there was no association between type 
of mutation and outcome. Furthermore, the same genotype can present with variable 
phenotypes. Indeed, asymptomatic children carrying the same mutation of their affected 
siblings have been recently published15 and herein reported (siblings carrying the c.1190 
G>A mutation). Future prospective studies should be considered to better understand the 
functional effects of each FOXP3 mutation, at disease onset and during disease course. 
Similarly, future studies should focus on evaluating the effect of different 
immunosuppressive regimens on the regulation of FOXP3 expression and its epigenetic 
modification such as demethylation at the Treg cell–specific demethylated region, which is 
essential to maintain Treg cells’ identity.33,34
Overall, this retrospective study instructs that rapamycin should be the preferred choice as IS 
treatment, while HSCT should be considered in patients with low OI score and stable 
clinical conditions. In conclusion, our comprehensive description of the natural history of 
IPEX and comparison of the effects of IS and HSCT may assist in determining therapeutic 
choices for these complex patients.
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Key messages
• Pretreatment organ impairment score in IPEX best predicts overall survival 
after HSCT.
• HSCT and IS recipients experience similar overall survival, but those 
receiving HSCT demonstrate higher rates of disease-free survival.
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FIG 1. 
Patients’ demographics and disease-related characteristics. A, Diagnostic delay scatter plot 
displaying correlation between age at diagnosis and age at onset (n = 96). Spearman’s rank 
correlation ρ = 0.456, P < .001. B, Histogram distribution of number of patients diagnosed 
between 2001 and 2015. Overlaid density distribution showed in blue. C, Heat map of 
number of symptoms at onset grouped by age at onset. Symptoms present in each age group 
(indicated by rows) were scaled (z-score or standardized score) and then converted to colors 
from yellow (low = less frequent) to red (high = highly frequent). Data were not available 
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(NA) for 3 patients; 1 patient has the mutation but has not yet experienced the onset; and for 
2 patients, the first symptom is unknown. D, Bar graph comparing frequency of symptoms at 
onset and later during disease evolution. Every bar indicates number of patients presenting 
each symptom. However, each patient can exhibit >1 symptom at once. E, Uncommon 
manifestations. Every bar indicates number of patients presenting each symptom. F, Scatter 
plot of FOXP3 gene mutations grouped by domain, indicating age at onset (circles) and 
number of symptoms at onset (asterisks), with median (n = 87; for 10 patients, cDNA 
FOXP3 mutations were not specified). Gene structure: N-terminal proline-rich (PRR) 
domain (orange), zinc-finger (ZF) domain (green), leucine-zipper (LZ) domain (blue), LZ-
FKH loop (yellow), and FKH domain (red). Mutations were grouped as follows: <c.1 to c.
570> 5 E1-5 N-terminal domain, <c.591 to c.666> = E5-6 ZF domain, <c.717 to c.780> = 
E6-7 LZ domain, <c.781 to c.1010> = E7-9 LZ-FKH loop domain, <c.1011 to c.1251> = 
E9-11 FKH domain. AIHA, Autoimmune hemolytic anemia; AIN, autoimmune neutropenia; 
AT, autoimmune thyroiditis; FTT, failure to thrive; ITP, idiopathic thrombocytopenic 
purpura; Neph, nephropathy; LN, lymphadenopathy; PRR, proline-rich region; UTR, 
untranslated region.
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FIG 2. 
Timeline of natural history and disease evolution. Patients undergoing HSCT (A) and IS (B). 
Each line represents a patient identified by his FOXP3 mutation in order of localization on 
the gene. The end on the line represents the last day of follow-up, and different symbols 
represent age at onset (circles) and age at HSCT (triangles) or the beginning of IS. An X at 
the end of the line indicates the age of death. The color of the line indicates the disease 
status after treatment, whether the patient went into remission (blue), was still diabetic 
(gray) or not cured (red). NA, Not available.
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FIG 3. 
Immunosuppressive therapy. A, Bar graph indicating numbers of patients exhibiting 
response, partial benefit, or no response according to a specific immunosuppressive drug 
administered (n = 34; however, each patient received >1 drug). B, Bar graph indicating each 
patient’s outcome after treatment with a combination of drugs, as last treatment. Each bar 
represents the number of patients receiving the treatment, distinguishing those in remission 
from those with additional or persistent autoimmunity (n = 34). C, Pre- and post-IS patients’ 
conditions, each bar represents the number of patients presenting each condition. On the 
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right side, the relative percentage is reported (n = 34; however, each patient could present 
with >1 condition at once). D, Percentage of survival for patients undergoing IS (n = 34) 
according to score post-IS (P = .0444). AZA, Azathioprine; Ca Inhib, calcineurin inhibitors; 
CTLA, cytotoxic T lymphocyte–associated antigen; MTX, methotrexate; MMF, 
mycophenolate mofetil; “others”, any different IS (eg, 6-mercaptopurina, mesalazine); 
RAPA, rapamycin.
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FIG 4. 
Survival analysis of patients undergoing HSCT. Percentage of survival of patients 
undergoing HSCT (n = 58) according to conditioning (log-rank test, P = .234) (A), donor 
type (P = .886) (B), age at HSCT (P = .359) (C), score pre-HSCT (P = .003) (D), score and 
conditioning (P = .010) (E), and score and age at HSCT (P = .019) (F). A survival 
probability table accompanies those plots that show significant differences (time points: 6 
months, and 1, 3, 5, and 10 years). Full C, Full conditioning regimen; MMRD, mismatched 
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related donor; MMUCB, mismatched unrelated cord blood; MMUD, mismatched unrelated 
donor; MSD, matched sibling donor; MUD, matched unrelated donor.
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FIG 5. 
Probability of survival and disease status after treatment. A, Survival analysis of IPEX 
patients undergoing HSCT or IS (n = 92, P = .055). B, Disease-free survival analysis of 
IPEX patients undergoing IS or HSCT censored for deaths (n = 81, P = .419).
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TABLE I
Biological findings characterizing the IPEX patients’ cohort before therapy
Immunophenotype pre-IS Median; range
(no. Of patients tested)
Lymph tot/mmc 2925; 900-7480 (22)
CD3+/mmc 2047; 600-4838 (23)
CD3+CD4+/mmc 1276; 370-3658 (24)
CD3+CD8+/mmc 586; 210-2020 (23)
Ratio CD4:CD8 2; 0.5-3.9 (23)
CD19+/mmc 276; 0-1715 (22)
CD16+CD56+/mmc 170; 20-525 (21)
CD4+CD25+, % 9; 0-35 (10)
CD4+CD25+CD127low, % 3; 1-6.6 (5)
FOXP3+, % in CD4+CD25+CD127low 36; 2.2-58 (5)
FOXP3+, % in CD4+ 5; 0.8-7 (4)
Immunophenotype pre-HSCT
Lymph tot/mmc 3350; 440-8189 (39)
CD3+/mmc 2185; 350-9388 (52)
CD3+CD4+/mmc 1311; 150-7824 (52)
CD3+CD8+/mmc 781; 106-2612 (51)
Ratio CD4:CD8 1.9; 0.3-10.1 (51)
CD19+/mmc 572; 0-6245 (51)
CD16+CD56+/mmc 200; 0-1112 (45)
CD4+CD25+, % 13; 0-49 (18)
CD4+CD25+CD127low, % 7.8; 3.3-20.2 (4)
FOXP3+, % in CD4+CD25+CD127low 50; 1.3-98 (9)
FOXP3+, % in CD4+ 0; 0-5 (3)
Gut biopsies before therapy (tot n = 61) No. of cases
Number of sites involved
 Single 26
 Multiple 34
Affected sites
 Esophagus 7
 Stomach 16
 Small bowel 45
 Large bowel 16
 All sites 7
Combinations of affected sites
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Gut biopsies before therapy (tot n = 61) No. of cases
 Small and large bowel 11
 Stomach + small bowel 9
 Stomach + large bowel 1
 Esophagus + stomach 1
 Esophagus + small bowel 2
 Stomach + small and large bowel 2
 Esophagus + stomach + small bowel 1
 Esophagus + small and large bowel 1
Infiltrating cell type
 Eosinophils 19
 Lymphocytes 32
 Plasma cells 8
 Polymorphonucleated cells 6
 Polymorphic infiltrate including all cells 8
 Unspecified inflammatory cell type 4
Histological lesions
 Villous atrophy 42
 Loss of goblet cells 3
 Crypt hyperplasia 9
 Crypt abscesses 8
 Ulcers 9
Gut biopsies before therapy (tot n = 61) No. of cases
 Loss of parietal cells 2
 Metaplasia 4
Enteropathy-related autoantibodies No. positive/No. of cases tested
Antienterocyte Abs 25/34
HAA 13/24
Antienterocyte and HAA 4/5
VAA 1/12
Other autoantibodies before therapy
Tot no of patients tested for GAD 41
 GAD among pts with T1D 15/18
 GAD among pts without T1D 9/23
Tot no. of patients tested for IA 27
 IA among pts with T1D 9/15
 IA among pts without T1D 0/12
Tot no. of patients tested for IAA 33
 IAA among pts with T1D 10/13
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Other autoantibodies before therapy
 IAA among pts without T1D 3/20
Tot no. of patients tested for ZNT8 14
 ZNT8 among pts with T1D 1/8
 ZNT8 among pts without T1D 0/6
Tot no. of patients tested for ICA 6
 ICA among pts with T1D 1/3
 ICA among pts without T1D 3/3
GAD, Glutamic acid decarboxylase autoantibodies; HAA, antiharmonin autoantibodies; IA, islet antigen; IAA, anti-insulin autoantibodies; ICA, 
anti-islet cell antibodies; mmc, mm3; pts, patients; tot, total; VAA, antivillin autoantibodies; ZNT8, zinc transporter 8 autoantibodies.
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TABLE II
Characteristics, outcomes, and complications of HSCT
No. patients Percent
Characteristics
 Tot no. of patients       58
 Age (y) at transplant, median (range) 1.4 (0.2-18.8)
Patients who received multiple transplants
 2 HSCT         7
 3 HSCT         1
Conditioning
 Full       27 47
 RIT       31 53
Donor-related; unrelated
 Matched 10; 21 17; 36
 1 MM   1; 13 2; 22
 2 MM     0; 6 0; 10
 3 MM     1; 1 2; 2
 Haplo     5; 0 9; 0
HSC source
 BM       35 60
 PB       11 19
 CB       12 21
Cell doses
 BM (TNC × 108/kg), median (range) 7.1 (0.01-91.3)
 PB (CD34 × 106/kg), median (range) 11.4 (4.3-40)
 CB (TNC × 107/kg), median (range) 9.8 (0.6-42)
Serotherapy
 ATG       22 38
 Alm       27 46
 None         9 16
GvHD prophylaxis
 CSA + MMF       18 31
 CSA + steroids       10 17
 CSA         6 10
 MTX + CSA (with or without short course of steroids)         8 14
 MTX + FK506 1 steroids         7 12
Others         9 16
Bone marrow recovery
 Neutrophils (days after HSCT), median (range) 16 (3-33)
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No. patients Percent
 Platelets (days after HSCT), median (range) 20 (5-114)
Immunoreconstitution
 Patients with T cells > 1000/mmc at 1 y 22 of 33
 Positive PHA response (months after HSCT), median (range) 14.5 (3-60)
 Independence from IVIg substitution (months after HSCT), median (range) 7 (1-48)
Use of donor stem cell boost         3
Use of donor lymphocytes infusion         3
Complications
 Transplant-related toxicity*       11 20
 Infections       46 79
 Tot GvHD,       21 36
  aGvHD (grade I-IV)       19 33
   aGvHD (grade III-IV)         9 16
  cGvHD         6 10
  No GvHD       37 64
Deaths       15 26
Alm, Alemtuzumab; aGvHD, acute graft-versus-host disease; ATG, antithymocyte globulin; BM, bone marrow; CB, cord blood; cGvHD, chronic 
graft-versus-host disease; CSA, cyclosporine; FK506, tacrolimus; Full, full conditioning regimen; IVIg, intravenous immunoglobulin; MM, 
mismatch; MMF, mycophenolate mofetil; MTX, methotrexate; PB, peripheral blood; PHA, phytohemagglutinine; TNC, total nucleated cells.
*
Toxicity after HSCT consisted of mucositis, pneumonitis, posterior reversible encephalopathy, undefined hypertrophic cardiomyopathy, 
nephropathy, and hepatic sinusoidal obstruction syndrome.
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